Diabetes Mellitus Management by the Egyptian Cardiologists: An Egyptian Survey | ||||
| NILES journal for Geriatric and Gerontology | ||||
| Volume 8, Issue 4, September 2025, Page 383-396 PDF (381.18 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/niles.2025.391408.1120 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Alaa Ahmed Ghaleb1; Shehab E. Etriby2; Adel E.Etriby2; sharaf eldeen shazly mahmoud3; Ahmed Elsharawy Ahmed   1
| ||||
| 1Cardiology Department, Sohag university | ||||
| 2cardiology department Ain Shams University | ||||
| 3sohag university hospital cath lab sohag , elnoor cardiac centre | ||||
| Abstract | ||||
| Background : Cardiologists currently see more patients with diabetes mellitus (DM) than endocrinologists. This study aimed to investigate the current management trends of DM among Egyptian cardiologists.Methods: A questionnaire was mailed to a random sample of cardiologists from district hospitals across Egypt, and 58 practitioners completed it. The questionnaire included 24 questions about participants’ knowledge of treating DM and novel therapies and the choice of oral antidiabetics as first-line or add-on therapy. A separate question investigates using the newer protective agents. Results: More than 20% of patients encountered by 90% of the practitioners had DM. Nearly half of the practitioners believe cardiologists have sufficient knowledge to address DM with novel treatments, and 60% believe diabetes-related education has gained recent consideration. About one-third of practitioners manage patients with type 1 DM, which was the primary motive (43.1%) for referral to endocrinologists. The primary aim of most practitioners (72%) when they counter the treatment of patients with T2DM was cardiorenal protection. Metformin was the first-line choice of 34 practitioners (58.6%), followed by SGLT2i (37.9%), and for patients with multiple risk factors, SGLT2i was recommended by 44 practitioners (76%). SGLT2 inhibitors were the primary add-on therapy chosen by 43 practitioners (74%).In T2DM-controlled patients, 54 practitioners (93.1%) selected to shift to the newer cardioprotective agents. Conclusion: The respondent cardiologists encounter a large number of diabetic patients among their cardiac patients, probably more than an endocrinologist can see in his daily practice. They were aware of the new cardioprotective antidiabetic agents and recommended their use. | ||||
| Keywords | ||||
| SGLT2; cardiology; Diabetes Mellitus | ||||
|
Statistics Article View: 54 PDF Download: 24 |
||||
